Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative Assessment of Overall Survival in Medicare Patients With HR+/HER2- Metastatic Breast Cancer Treated With Palbociclib in Combination With Aromatase Inhibitor (AI vs. AI Alone)

NCT06086340 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06086340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06086340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative Assessment of Overall Survival in Medicare Patients With HR+/HER2- Metastatic Breast Cancer Treated With Palbociclib in Combination With Aromatase Inhibitor (AI vs. AI Alone)
Lead sponsor
Pfizer
Phase
Observational
Overall status
Completed
Start date
September 29, 2023
Completion date
January 24, 2024
Enrollment
779 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer